Abstract

NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy because no evidence submission was received from Merck Sharp & Dohme. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance